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1. Introduction  
Mycotoxins are secondary metabolites produced by fungi that grow naturally in foodstuffs. 
They are able to generate a wide variety of toxic effects in vertebrates, including men 
(Coulombe, 1991). Toxigenic fungi may contaminate foodstuffs in the most different phases 
of production and processing, from cultivation to transport and storage. Mycotoxins show 
high chemical stability and may persist in the foodstuff even after fungi were removed by 
common manufacturing and packaging processes (Chu, 1991). 
Diseases caused by mycotoxins are called mycotoxicoses. They are diffuse syndromes that 
cause lesions mainly in organs such as liver, kidneys, epithelial tissue (skin and mucous 
membranes) and central nervous system, depending on the type of the toxin. Two or more 
toxins may also occur simultaneously, leading to intensified toxic effects on the susceptible 
organism (Orsi et al., 2007).  
Aflatoxins are mycotoxins produced by fungi in the genus Aspergillus, species A. flavus, A. 
parasiticus and A. nomius (Moss, 1998). These fungi are distributed worldwide, and their 
optimal growth conditions are relative humidity of 80-85% and temperature around 30ºC 
(Coulombe, 1991).  
Nowadays, 18 similar compounds are called aflatoxins. However, the most important in 
medical terms are types B1, B2, G1 e G2 (Coulombe, 1991). Aflatoxin B1 (AFB1), besides being 
the most frequently found in plant substrates, has the greatest toxigenic power. Aflatoxins 
B2 (AFB2), G1 (AFG1) and G2 (AFG2) have about 50, 20 and 10% of AFB1 toxigenic power, 
respectively (Leeson et al., 1995). 
AFB1 is a genotoxic compound, and is considered to be one of the most potent natural 
mutagens. Liver carcinogenesis is the most important effect of chronic aflatoxin exposure.  This 
toxicity has been widely demonstrated – mainly in relation to AFB1 - in many animal species, 
including fish, birds, rodents, carnivores and primates (Busby & Wogan, 1984). Based on 
available studies, the International Agency for Research on Cancer (IARC) concluded, in 1987, that 
there was enough evidence to classify AFB1 in Group 1 - human carcinogen (Rothschild, 1992) 
One of the most important aspects in risk analysis of chemical substances is to determine the 
degree of human exposure (World Health Organization [WHO], 2002), a particularly 
difficult task for contaminants present in foodstuffs. However, it is possible to indirectly 
estimate the degree of exposure based on data on consumption of contaminated foodstuffs, 
and on the average occurrence of the toxin. In this estimation, the degree of exposure is 
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measured in terms of probable daily intake (PDI) per unit of body weight, and is generally 
expressed in ng/kg of body weigh (BW) / day. In risk analysis, PDI is compared with 
tolerable daily intake (TDI) determined in toxicological studies. In spite of the genotoxic 
characteristic of this toxin, there is no consensus on tolerable daily intake of AFB1.  
Taking into account aflatoxin toxicity and the lack of an established TDI, several countries 
determined regulations on maximum aflatoxin levels allowed in foodstuffs. Table 1 
summarizes some data of a report by the Food and Agriculture Organization of the United 
Nations (FAO, 2004). It may be noted that the European Community and the Mercosur 
standardized their regulations, although some countries kept some food items with additional 
country regulations. Foodstuffs characteristic of each country, frequency of consumption of 
these items and climate characteristics apparently influence maximum limits adopted in each 
region, although there is a consensus that these limits should comply with the ALARA (as 
lowest as reasonable accepted) criterion recommended by the FAO (2004).  
2. AFB1 biotransformation 
Biotransformation is a process by which the body transforms foreign substances 
(xenobiotics) in new chemical compounds (metabolites), that is, a process in which the initial 
compound is modified to be eliminated by the biological system (Guenguerich, 1999). After 
oral ingestion, AFB1 is efficiently absorbed and biotransformed before urinary and fecal 
excretion (Figure 1).  
Absorbed AFB1 and its metabolites are excreted in urine and feces. Breastfeeding mothers who 
consume contaminated foodstuffs may also shed aflatoxins metabolites in their milk. Studies 
in animals demonstrated that in normal conditions, 50% of AFB1 oral dose is quickly absorbed 
in the duodenum and reach the liver by the portal system (Wilson et al., 1985). AFB1 is 
concentrated in the liver and, in lesser amounts, in the kidneys. It may also be found in 
mesenteric venous blood as free AFB1 or as water-soluble metabolites (Wogan et al., 1967).  
Enzymes of the cytochrome P450 (CYP) family, CYP1A2, CYP3A4 and CYP2A6, are 
responsible for the biotransformation of absorbed aflatoxins (Essigmann et al., 1982). These 
enzymes convert AFB1 into its carcinogenic form, AFB-8,9-epoxide, which bonds covalently 
to DNA and serum albumin, producing AFB1-N7-guanine and lysine adducts, respectively 
(Essigmann et al. 1977; Sabbioni et al. 1987). The bond between AFB1 and DNA modifies the 
structure and biological activity of DNA, leading to the basic mutagenic and carcinogenic 
mechanisms of the toxin. Studies with rat livers showed that AFB1-N7-guanine adducts may 
be removed after they are formed, leaving apurinic sites in the DNA molecule (Hsieh et al., 
1991). Vacant sites tend to be filled with adenine, causing a guanine to thymine transversion 
and generating a highly significant point of mutation (Aguillar et al., 1993).  
Besides being epoxided, AFB1 can be also oxidized into several other derivatives. The main 
hydroxylated metabolites are aflatoxin M1 (AFM1), aflatoxin Q1 (AFQ1), a demethylated 
metabolite, aflatoxin P1 (AFP1), and a reduced metabolite, aflatoxicol (Figure 1).  AFM1 may 
be activated to form AFM1-8,9-epoxide, which binds to DNA and is excreted in urine as 
AFM1-N7-guanine (Egner et al, 2003). AFQ1 and AFP1 are not significantly oxidized by 
human microsomes, and are not considered to be genotoxic (Raney et. al, 1992).  Metabolites 
AFM1, AFQ1 and AFP1 are not good substrates for epoxidation, are less genotoxic than AFB1, 
and consequently, are considered detoxification products. However, because of the high 
toxicity reported for AFM1, researchers should be cautious when labeling this compound a 
“detoxification product” (Neal et al., 1998).  
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Country Food Product Mycotoxin 
Limit 
(µg/kg) 
United States  All foods except milk
 
Milk
AFB1, AFB2, AFG1, AFG2 
 
AFM1 
20 
 
0.5 
Canada Nuts and nut products AFB1, AFB2, AFG1, AFG2 15 
Mercosur (Brazil, 
Argentina, 
Paraguay and 
Uruguay) 
Peanuts, maize, and maize products 
 
Fluid milk 
Powdered milk 
AFB1, AFB2, AFG1, AFG2 
 
 
AFM1 
20 
 
 
0.5 
5 
Bosnia & 
Herzegovina 
Wheat, maize, rice and cereals
Beans
AFB1, AFG1 1 
5 
China Maize and maize products, peanut and 
peanut products, peanut oil, irradiated 
peanut 
 
Rice, irradiated rice, edible vegetable oil 
 
Soy bean sauce, grain paste, vinegar, other 
grains, beans, fermented foods, fermented 
bean products, starch products, fermented 
wine, red rice, butter cake, pastry biscuit and 
bread, food additive alpha-amylase, food 
additive glucoamylase preparation, salad oil
AFB1 20 
 
 
 
10 
 
 
5 
India All food products AFB1, AFB2, AFG1, AFG2 
and AFM1
30 
European Union Groundnuts, nuts and dried fruits, 
processed products intended for direct 
human consumption or as 
ingredients in foodstuffs
AFB1 
AFB1, AFB2, AFG1, AFG2 
2 
4 
Australia and 
New Zealand 
Peanuts and tree nuts AFB1, AFB2, AFG1, AFG2 15 
Chile All foods
 
Milk
AFB1, AFB2, AFG1, AFG2 
 
AFM1
5 
 
0.05 
Japan  All foods AFB1 10 
Israel Nuts, peanuts, maize flour, figs and their 
products, and other foods 
 
 
Milk and milk products
AFB1 
AFB1, AFB2, AFG1, AFG2 
 
 
AFM1
5 
 
15 
 
0.05 
Italy Infusion plants
 
 
Baby food
AFB1 
AFB1, AFB2, AFG1, AFG2 
 
AFM1
5 
10 
 
0.01 
Mexico Cereals and cereal products
Corn flour for tortillas
AFB1, AFB2, AFG1, AFG2 20 
12 
EU member states: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, 
Luxembourg, the Netherlands, Portugal, Spain, Sweden, the United Kingdom 
Table 1. Limits for mycotoxin contamination in food products destined for human 
consumption in different countries. 
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Source: Adapted from Mykkanen et al., 2005.  
Fig. 1. Pathways of aflatoxin B1 biotransformation and excretion in humans. 
(a) Experimental and human evidendence of excretion of this metabolite; (b) Scarce or no 
evidence available; (c) only experimental evidence available (no data for humans). 
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3. Role of aflatoxins in the etiology of hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) represents more than 80% of primary malignant tumors of 
the liver, and it is the 7th to 9th most common type of cancer worldwide affecting men and 
women, respectively. About 315,000 new cases of HCC are reported annually, a total of 4.1% 
of all malignant tumors in the world population. Although it is a relatively uncommon 
tumor, HCCs are aggressive, and mortality rates reach significant values, with about 312,000 
deaths a year, and maximal survival rates of 5% in 5 years.  Occurrence of HCC is associated 
with some degree of chronic liver disease in 90% of the cases, and it is an important cause of 
death in cirrhosis patients.  HCC incidence has been growing, and may be directly related to 
the frequency of hepatitis C virus infection and longer survival of cirrhosis patients (Yang & 
Roberts, 2010). 
HCC incidence in Africa and southeastern China is far greater than in the rest of the world. 
Besides known risk factors of western countries such as viral hepatitis and alcohol 
consumption, these populations are exposed to aflatoxin. The toxin is ingested in 
contaminated and stored foodstuffs, such as peanuts, maize, soybeans and rice. The 
association between AFB1 and HCC is based on the ability of the toxin to induce a specific 
mutation of gene p53 (Bressac et al., 1991).  
In Brazil, HCC is not included among the ten most common types of cancers, probably 
because of underreporting. Estimates show that there are 2 to 3,000 diagnoses of the disease 
every year, with a national incidence of 1:100,000 inhabitants/year. Incidence of this 
neoplasm is greater in the north, northeast and southeast than in the south of the country. 
The greatest frequency occurs in the states of Amazonas, Bahia and Espírito Santo. (Pimenta 
& Massabki, 2010). In São Paulo, incidence is a little greater than the mean of the country, 
affecting about 2:100.000 inhabitants/year.  In terms of mortality, HCC is the 7th death cause 
and is responsible for 4% of the deaths by cancer in Brazil, annually. HCC incidence rate in 
Brazil is associated with advanced cirrhosis in 71.2% of the cases, as observed in the rest of 
the world. However, serology for viral hepatitis is negative in 42% of the cases HCC, even 
with regional discrepancies (Gonçalves et al., 1997). This difference may be related to the 
exposure to AFB1. This relationship, however, was not analyzed in the whole country.  
Apparently, HCC progress is not an occasional event. Hepatocarcinogenesis seems to be a 
multifactorial process in which extrinsic stimuli induce gene changes in mature hepatocytes, 
leading to successive proliferation and cell death cycles that culminate in the production of 
monoclonal populations. Several lines of evidence suggest that hepatocarcinogenesis may 
begin in preneoplastic lesions, such as regenerative macronodules and low or high grade 
dysplastic nodules. Accumulation of genetic changes and new mutations in preneoplastic 
lesions would probably cause HCC (Theise et al., 2002).  
In molecular terms, many derangements observed in HCC may be preferentially attributed to 
cirrhosis and inflammatory activity, and others are inherent to dysplastic nodules and to HCC 
itself. In early stages of chronic hepatitis, there are significant changes in the expression of 
growth factors, proteases and metalloproteinases, besides somatic changes, reduced apoptosis 
and increased expression of oncogenes and transcriptional factors. In general, these changes 
become more prominent and complex as the lesion progresses to fibrosis, cirrhosis, dysplastic 
nodules and, finally, HCC (Coleman, 2003). No tumor-suppressor gene exclusively associated 
with HCC has been identified. However, all molecular changes accumulated by chronic 
hepatitis and cirrhosis in repeated aggression / regeneration cycles, directly contribute to 
hepatocarcinogenesis (Fausto & Weber, 1993). Aneuploidy is also a common event in 
hepatocarcinogenesis. HCC is characterized by a considerable loss of heterozygosity, and 
includes several chromosomes, such as 1p, 4q, 6q, 8p, 8q, 9p, 13q, 16p, 16q, and 17p. Mutations 
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in several critical genes , such p73, p53, Rb, APC, DLC-1 (deleted in liver cancer), p16, GSTP1, 
PTEN, IGF-2, BRCA2, SOCS-1, Smad2 and Smad4, -catenine, c-myc, and cyclin D1 were also 
identified (Fujimori et al., 1991; Tsuda et al., 1992).  
Impaired control of cell cycle is an important event in carcinogenesis. The first observations 
involving carcinogenesis and cyclins were related to detection of the incorporation of 
Hepatitis B virus DNA to cyclin A gene in HCC (Wang et al. 1990), and to amplification of 
cyclin D1 gene in some cell lineages of colon carcinoma (Leach et al., 1993). The p16/cyclin 
D1/RB pathway (retinoblastoma) may be considered the greatest cell cycle regulator. RB and 
p16 act as tumor supressor genes, and cyclin D1 as an oncogene (Weinberg, 1995; Ito et al., 
1999). Aberrant expression of both cyclin-dependent kinases (CDK) and CDK-inhibitors has 
an important role in HCC development. High expression of cyclin D1 in HCC is variable, 
ranging from 6 to 76% in different studies. Among positive regulators of cell cycle, changes 
in cyclin D1, A and B1 expression compared with normal tissues have been associated with 
increased cell growth and development of neoplasms (Ito et al., 1999). 
Analysis of aberrant expression of cyclin D1, its biological role and its relationship with 
mutations in p53 in cases of HCC demonstrated that cyclin D1 of was normally expressed in 
healthy livers, but it was highly reduced in 40% of the livers affected by HCC (Peng et al., 
1998). Lower expression of cyclin D1 RNAm was associated with larger and less 
differentiated tumors. Increased expression of cyclin D1 was observed in only 5.6% of the 
cases. On the other hand, cyclin E shows increased expression in 56% of the HCC cases.  
Overexpression of cyclin E was associated with little differentiation and with invasiveness, 
but not with tumor volume. Thus, decreased expression of cyclin D1 and increased 
expression of cyclin E are intimately associated with mutation in p53. Besides, 
overexpression of cyclin E and concomitant loss of p53 function seem to contribute to HCC 
progression (Peng et al., 1998 ; Jung et al., 2001).  
There are three important inhibitors of cell cycle progression in the Cip/Kip family: p27KIP1, 
p21WAF1, and p57KIP2. The most comprehensively studied of these inhibitors, in terms of 
clinical significance in the evolution of human cancer, is p27KIP1. Expression of p27KIP1 is 
marked in non-proliferating cells, and it has important roles in the regulation of both 
quiescence and progression in G1 phase, by means of inhibition of cyclin / CDK complexes.  
Loss of p27KIP1 acts together with mutations of several oncogenes and suppressor genes, 
stimulating tumor growth. Reduced production of the protein synthesized by p27KIP1 is 
significantly involved in the stage and volume of primary tumors. Thus, p27KIP1 has been 
described as a crucial negative regulator of HCC progression. Its increased expression is 
considered an independent variable in favorable prognosis of HCC (Ito et al., 2001; 
Fiorentino et al., 2000). Reduced p21WAF1 expression is mainly related to mutation in gene 
p53 in HCC, and also contributes to hepatocarcinogenesis.  However, p21WAF1 loss was not 
identified as an independent factor in HCC bad prognosis (Ito et al., 2001).  Compared with 
healthy livers, expression of p57KIP2 is significantly decreased in HCC lesions. This decreased 
expression of p57KIP2 was associated with highly aggressive tumors, characterized by more 
advanced stages, little differentiation, larger size, portal invasion, intense cellular growth 
and low disease-free survival rates (Ito et al., 2001)  
In terms of frequency, the most common molecular changes observed in HCC cases are p53 
(20-70%), cyclin D (11%), p16Ink4 (0-50%), Rb (15%) and β-catenin (16-26%), from which only 
p53 mutation was reported to be associated with hepatitis B virus gene interaction and 
exposure to aflatoxin (Ozturk, 1999).   
Although mutations in p53 pathway have an important role in HCC pathogenesis in cases of 
cirrhosis, changes in cell cycle regulator genes p21waf1/cip1 and p27Kip1 are more involved in 
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HCC cases unrelated to cirrhosis (Tretiakova et al., 2010). These cases could be, in part, 
attributed to aflatoxin. Therefore, other molecular changes in genes p21waf1/cip1 and p27Kip1 
should also be assessed in individuals exposed to aflatoxin.  
4. Biomarkers of aflatoxin exposure 
Biomarkers measure cellular, biological or molecular changes in biological tissues, cells or 
fluids, providing information on disease or exposure to a given substance. As biomarkers 
are used to measure or indicate biological processes, detection of specific biomarkers may 
aid identification, diagnosis and treatment of individuals who are affected and at risk, but 
still asymptomatic. Development of biomarkers for environmental agents should be based 
on specific knowledge on metabolism, formation of by-products and general mechanism of 
action (Groopman & Kensler, 1999).  
Biomarkers may be classified in four categories: internal dose, biologically effective dose, 
early biological response, and altered structure/function. (Figure 2). Internal dose is the 
amount of substance that is metabolized.   Individual characteristics determine susceptibility 
to exposure, such as the ability to activate / detoxify carcinogens, ability to repair DNA 
changes, nutritional status and immunity, age, sex and socioeconomic status (WHO, 1993). 
 
 
Source: Adapted from Groopman & Kensler (1999) 
Fig. 2. Classification of biomarkers.   
Biomarkers of exposure and effect for aflatoxins have been validated in comprehensive studies 
in animals and humans. Dose-response relationship between AFM1 and AFB1-N7-guanine 
levels and incidence of liver tumors was first established in animals (Groopman et al., 1992b). 
Biomarkers were then evaluated in humans to determine sensitivity, specificity, accuracy and 
reliability parameters. Later validation in epidemiological studies evaluated intra and inter-
subject variability, the relationship biomarker–external dose and the feasibility of using them 
in large population studies (Groopman et al., 1992a; Groopman et al., 1992c).  
In a study carried out in Shanghai, People’s Republic of China, 18,244 volunteers were 
followed up for three years. The analysis included individual interviews on eating habits, 
possible previous exposure to aflatoxins, and collection of urine samples (Ross et al., 1992; 
Qian et al., 1994). Cases and controls were compared to detect associations between 
aflatoxin markers, infection by Hepatitis B virus (HBV), and hepatocellular carcinoma.  Data 
showed a 340% increase in the relative risk for HCC when aflatoxin biomarkers were 
detected in urine. Relative risk in individuals showing positive results for HBV was 730% 
greater. Subjects who showed aflatoxin markers in urine and were positive for HBV 
infection had a relative risk of developing HCC 5,900% greater. These data support the 
relationship between the two major causes of HCC: HBV infection and exposure to AFB1. 
Besides, when individual metabolites were stratified for HCC incidence, the presence of 
AFB1-N7-guanine adduct led to 200 to 300% increase in the relative risk of developing HCC. 
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After the Shanghai study, a trial developed in Taiwan with about 15,000 volunteers also 
analyzed the relationship between HBV, exposure to AFB1, and incidence of HCC; the 
results of this trial confirmed the findings of the previous study (Yu et al., 1997).  Risk of 
developing HCC along with AFB1 exposure was more pronounced among those individuals 
infected by HBV and with detectable levels of AFB1-N7-guanine in their urine.    
5. Occurrence of aflatoxin biomarkers in biological fluids 
In past decades, several studies reported the presence of aflatoxins, metabolites and 
biomarkers in urine (Table 2). Zhu et al. (1987) analyzed 252 urine samples from inhabitants 
of Guangxi province, People’s Republic of China, and reported a correlation between total 
daily ingestion of AFB1 and excretion of AFM1. Between 1.2 and 2.2 of AFB1 ingested daily 
was found in urine as AFM1, in levels ranging from 0 to 3.2 ng/mL. In a later study, the 
same urine samples were analyzed again and levels of AFB1-N7-guanine adduct were also 
correlated with AFB1 ingestion (Groopman et al., 1992c). Total amounts of AFB1-N7-guanine 
excreted in urine in a three-day period ranged from < 50 and 3250 ng and about 0.2% of 
AFB1 ingested was excreted in urine as AFB1-N7-guanine. In the same study, levels of the 
metabolite AFP1 did not show a significant statistical correlation between dietary exposure 
and excretion in urine, and the metabolite AFQ1 was observed in few samples. Percentage of 
AFB1 excreted in urine as any of these metabolites was 4.4% in women and 7.6% in men.   
In another study, also carried out in Guangxi province, AFB1-lysine adduct was determined in 
serum samples of 42 inhabitants and compared with AFB1 ingestion and AFM1 excretion in 
urine (Gan et al., 1988). Significant correlation coefficients were found between AFB1-lysine 
levels in serum and AFM1 in urine, and between AFB1-lysine in serum and dietary exposure to 
AFB1. It is estimated that 1.4 and 2.3% of AFB1 ingested is covalently bound to albumin.   
Qian et al. (1994) detected 55 cases of hepatocellular carcinoma. From these cases, urine 
samples of 50 individuals and 267 control samples were analyzed for levels of AFB1-N7-
guanine, AFM1, AFP1 and AFB1. The metabolite detected in the greatest concentration was 
AFP1, (0.59-16.0 ng/mL), whereas AFM1 ranged from 0.17-5.2 ng/mL, and 0.3 to 1.81 
ng/mL for AFB1-N7-guanine adduct.   
Wild et al. (1992) carried out a study with 20 individuals in Gambia, West Africa, and also 
confirmed the validity of AFB1-lysine as a biomarker. Parallel evaluation of the same 
individuals by Groopman et al. (1992a) for AFB1-N7-guanine in urine, confirmed not only 
the correlation between this metabolite and AFB1, ingestion, but also demonstrated the 
correlation between levels of AFB1-lysine in serum and AFB1-N7-guanine in urine. AFG1 was 
the most frequent metabolite observed in urine, as a consequence of the high concentration 
of aflatoxin found in the foodstuffs consumed by the individuals analyzed, compared with 
other studies in which the diet analyzed did not have AFG1. Besides, metabolites AFQ1 and 
AFP1 were also determined, and AFM1 was observed in some samples.   
Levels of AFB1-N7-guanine adducts in urine (Groopman et al., 1992a; Groopman et al., 
1992c) and AFB1-lysine in blood (Gan et al., 1988) show the biological effective dose of 
aflatoxin to which the individual has been exposed. Concentration of AFB1-N7-guanine in 
urine shows exposure to AFB1 in a 1 to 2-day period, whereas concentration of AFB1-lysine 
in serum indicates 2 to 3-month exposure (Wild et al., 1992).  
Urinary and fecal excretion of metabolites AFQ1 e AFM1 and urinary excretion of AFB1-N7-
guanine were evaluated in 83 university students in China (Mykkanen et al., 2005). Mean 
fecal AFQ1 concentration (137 ng/g, moist weight) was about 60 times greater than mean 
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AFM1 concentration (2.3 ng/g, moist weight). In urine, mean AFQ1 concentration was 10.4 
ng/mL, and 0.04 ng/mL and 0.38 ng/mL for AFM1 and AFB1-N7-guanine, respectively. The 
authors emphasized that, compared with other studies, differences in concentrations and 
frequencies of AFQ1 and AFM1 in their study may be attributed to differences in age and 
diet of the subjects. Participants of this study were young adults, 18-24 years of age, whereas 
in previous trials, individuals were 25 to 65 years old. Expression of CYP3A enzymes, which 
produce AFQ1, decreases about 25-40% with age in animals and humans, and consumption 
of foodstuffs rich in flavonoids, such as green tea, may increase AFQ1 formation by 
activation of these enzymes.   
In Brazil, Scussel et al. (2006) evaluated the presence of AFB1-lysine adduct in blood samples of 
50 subjects in the city of Sao Paulo, in 1999. The adduct was detected in 62% of the samples, in 
a concentrations ranging from 0 – 57.3 pg AFB1-lysine/ mg blood albumin. Mean 
concentration in positive samples was 14.9 pg/mg. Sixty-five urine samples from inhabitants 
of the city of Piracicaba, state of Sao Paulo, were analyzed for AFM1 and 65% of them showed 
concentrations greater or equal to 1.8 pg/mL, with mean concentration of 5.96 pg/mL 
(Romero et al., 2010). Correlation between probable aflatoxin intake - estimated by means of 
questionnaires on the frequency of consumption – and AFM1 levels in urine were not 
significantly correlated.  
AFM1 is also excreted in milk during lactation, and several studies demonstrated the 
presence of this metabolite in human milk.  In the Arab Emirates, AFM1 was detected in 
milk in concentrations ranging from 5 to 3400 pg/mL (Abdulrazzaq et al., 2003). In 
Australia, AFM1 levels ranged from 28 to 1031 pg/mL, and in Thailand, from 39 to 1736 
pg/mL (El-Nezami et al., 1995).  In a study carried out in Gambia (Zarba et al., 1992), 0.09 to 
0.43 % AFB1 ingested in the diet was excreted in milk as AFM1. In Brazil, this metabolite was 
studied in samples collected from human milk banks. From 50 samples analyzed, only one 
was contaminated by AFM1 at a concentration of 0.024 ng/mL (Navas et al., 2005).  In a 
recent study carried out with 160 lactating mothers in Iran, AFM1 was detected in 157 
samples, with concentrations ranging from 0.3 to 26.7 ng/kg (Sadeghi et al, 2009).  
Aflatoxins were also detected in samples of umbilical cord blood, demonstrating they can 
cross the placenta, starting exposure to this carcinogen in the uterus (Wild et al., 1991; 
Turner et al., 2007).  
Quantitative determination of several metabolites in complex matrices, such as serum and 
urine, requires specific and sensitive methods for a large number of samples. Particularly for 
AFB1-lysine adduct in serum, methods may include radioimmunoassay (RIA; Gan et al., 1988), 
enzyme linked imunosorbent assay (ELISA; Wild et al., 1992), or purification with 
immunoaffinity columns followed by separation by high performance liquid chromatography 
(HPLC) and detection by fluorescence (Wild et al., 1992; Wang et al., 1996). As all these 
methods require antibodies for detection and/or purification, results will necessarily reflect 
the capacity, specificity and/or sensitivity of the antibody (Wang et al., 2001). Results obtained 
using ELISA, RIA and fluorescence were significantly different (Sheabar et al., 1993; Wild et al., 
1990). ELISA is highly sensitive, but it is less specific and shows higher concentration of AFB1-
lysine due to the concomitant detection of adducts from reactions with other amino acids and 
ingestion of aflatoxins of similar structure, such as AFG1. HPLC-fluorescence is specific for 
AFB1-lysine, but it is not sensitive enough for epidemiological studies.   
A recently developed method combines solid phase extraction and liquid chromatography-
mass spectrometry (HPLC-MS/MS), showing high specificity and sensitivity (McCoy et al., 
2005). The method uses a stable isotope internal standard to correct recovery and equipment 
variability. This method showed to be adequate for routine quantification of adducts in 
human serum (Scholl et al., 2006b). 
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Table 2. Aflatoxins and metabolites in human urine and serum. (a) The unit is expressed 
only in the first row; (b) Only one positive sample; (c) Lactobacillus rhamnosus LC705 and 
Propionibacterium freudenreichii subsp. shermanii (1:1, m:m), 2 – 5 x 1010 colony forming 
units/d. NS, not specified; GTP, green tea polyphenols; alb, albumin; crea, creatinine. 
Methods used to determine AFB1-N7-guanine adduct include immunoassays (Groopman et 
al., 1992a), HPLC with UV detection (Groopman et al., 1992c), or fluorescence (Wang et al., 
1999; Mykkanen et al., 2005). Egner et al. (2006) described a method using HPLC-MS/MS in 
the analysis of AFB1-N7-guanine in urine, also based on the use of stable isotype internal 
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standard. Precision and accuracy were far superior than previous procedures. Together with 
the analysis of AFB1-lysin, determination of these two biomarkers in urine and serum 
samples is precise, accurate, specific and selective.  Determination of residual aflatoxin and 
metabolites AFM1, AFP1 and AFQ1 in urine has been carried out using HPLC-fluorescence 
(Tang et al., 2008; Polychronaki et al., 2008; Romero et al., 2010). However, HPLC-MS/MS 
has recently been used successfully to determine AFB1, AFB2, AFG1, AFG2, AFM1 and AFP1 
in urine (Everley et al., 2007).  
6. Concluding remarks 
Current concepts derived from intensive research on biotransformation, mechanisms of 
toxicity and evidence of the role of aflatoxins in the etiology of human liver cancer were 
summarily presented in this chapter. AFB1 exerts its effects after conversion to the reactive 
compound AFB1-epoxide by means of cytochrome P450-dependent enzymes. This epoxide 
can form derivatives with cellular macromolecules, including proteins, RNA and DNA. 
Reaction with DNA occurs with guanines in codon 249 of tumor suppressor gene p53. 
Although mutations in p53 pathway have an important role in HCC pathogenesis other 
molecular changes in genes p21waf1/cip1 and p27Kip1 should also be assessed in individuals 
exposed to aflatoxin. 
Primary biotransformation of AFB1 also produces hydroxylated and less toxic derivatives, 
such as aflatoxins Q1 and P1. Intra and interspecies differences in the pathways of 
activation/detoxification are directly related to the susceptibility of animals to aflatoxin 
effects. In humans, individual biomonitoring of AFB1 metabolites such as AFB1-N7-guanine 
have demonstrated that aflatoxins constitute an important risk factor for hepatocellular 
carcinoma in highly exposed populations. Some of these studies also show synergism 
between aflatoxins and hepatitis B virus in the development of human HCC. Based on these 
concepts, and taking into account the frequent detection of aflatoxins in foodstuffs 
worldwide, further investigations are needed to assess the level of dietary exposure to these 
toxins and its impact on human health. 
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